| scholarly article | Q13442814 |
| P356 | DOI | 10.1023/A:1008379500436 |
| P698 | PubMed publication ID | 10631471 |
| P50 | author | Athanasios Dimopoulos | Q26338766 |
| George Fountzilas | Q56432880 | ||
| P2093 | author name string | A Anagnostopoulos | |
| C Papadimitriou | |||
| G Aravantinos | |||
| P Kosmidis | |||
| V Georgoulias | |||
| A Giannopoulos | |||
| L A Moulopoulos | |||
| A Bamias | |||
| A Karayannis | |||
| C Bakoyannis | |||
| C Deliveliotis | |||
| D Pantazopoulos | |||
| I Varkarakis | |||
| A Zervas | |||
| Z Kyriakakis | |||
| P2860 | cites work | Reporting results of cancer treatment | Q29620070 |
| Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group | Q33488031 | ||
| Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma | Q33499366 | ||
| Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients | Q36115695 | ||
| A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study | Q40731377 | ||
| Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse | Q43419722 | ||
| Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. | Q53665742 | ||
| Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel | Q57905110 | ||
| A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors | Q68514585 | ||
| Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study | Q73494793 | ||
| Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study | Q77435874 | ||
| P433 | issue | 11 | |
| P921 | main subject | cisplatin | Q412415 |
| docetaxel | Q420436 | ||
| chemotherapy | Q974135 | ||
| P304 | page(s) | 1385-1388 | |
| P577 | publication date | 1999-11-01 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group | |
| P478 | volume | 10 |
| Q84058686 | Bladder cancer |
| Q36729145 | Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. |
| Q35227771 | Chemotherapy in advanced bladder cancer: current status and future |
| Q36636656 | Chemotherapy practices and perspectives in invasive bladder cancer |
| Q33418868 | Combination of docetaxel, ifosfamide and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma |
| Q37789085 | Current chemotherapeutic options for the treatment of advanced bladder cancer: A review |
| Q37888549 | Current chemotherapeutic strategies against bladder cancer |
| Q24799659 | Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial |
| Q37283563 | Emerging intravesical therapies for management of nonmuscle invasive bladder cancer |
| Q33364779 | Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study |
| Q37676223 | Investigational therapies for non-muscle invasive bladder cancer |
| Q41455651 | Maintenance treatment with gemcitabine have a promising activity on metastatic bladder cancer survival |
| Q46205666 | Metastases from urethelial carcinoma: role of chemotherapy |
| Q38729106 | Nanoparticle delivery of chemotherapy combination regimen improves the therapeutic efficacy in mouse models of lung cancer. |
| Q35192424 | New drugs and new approaches in metastatic bladder cancer |
| Q33341273 | Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer |
| Q35677288 | Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10-17). |
| Q36619428 | State-of-the-art management of metastatic disease at initial presentation or recurrence |
| Q78898958 | [Advanced bladder cancer: new therapeutic strategies] |
Search more.